Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties
about
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcriptCRKL binding to BCR-ABL and BCR-ABL transformationSignal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesisInteractions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potentialTransformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.cDNA sequence for human bcr, the gene that translocates to the abl oncogene in chronic myeloid leukaemiaRecombinant tumor necrosis factor alpha and interleukin 1 alpha increase expression of c-abl protooncogene mRNA in cultured human marrow stromal cells.Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residuesRapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosomeClinical applications of BCR-ABL molecular testing in acute leukemiaTyrosine kinase inhibitors as cancer therapy.Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patientsDuplication of the bcr and gamma-glutamyl transpeptidase genesSH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.Chronic myeloid leukaemia following repeated exposure to chest radiography and computed tomography in a patient with pneumothorax: A case report and literature review.Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.DNA sequence, structure, and tyrosine kinase activity of the Drosophila melanogaster Abelson proto-oncogene homologSelective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules.Low level of cellular protein phosphorylation by nontransforming overproduced p60c-srcExpression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related proteinExpression of a molecularly cloned human c-src oncogene by using a replication-competent retroviral vectorApplying the discovery of the Philadelphia chromosome.Receptor for bombesin with associated tyrosine kinase activity.Phosphotyrosine antibodies identify the p210c-abl tyrosine kinase and proteins phosphorylated on tyrosine in human chronic myelogenous leukemia cellsNormal cellular and transformation-associated abl proteins share common sites for protein kinase C phosphorylation.Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene productsA 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.RNAi screen for rapid therapeutic target identification in leukemia patients.Leukemia initiated by hemopoietic stem cells expressing the v-abl oncogene.Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome.Proto-oncogenes in development and cancer.c-src is consistently conserved in the chromosomal deletion (20q) observed in myeloid disordersChromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemiaCell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.Improving outcomes for high-risk ALL: translating new discoveries into clinical care.BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.Genomics of chronic neutrophilic leukemia.
P2860
Q24615435-4EBE78B4-D686-4D88-86B5-D3856B939D93Q28140785-49C71C69-1580-4F28-AE37-8F2BAC726A74Q30175784-8191F864-2063-4ABF-90B2-7CEF2AF80C30Q30176501-57F102D1-4CF1-4A45-A42D-6E4459E36381Q33557893-AD3FBD89-39C0-4EAF-A510-2C2FB7FC6B6FQ33682660-9FDFBFE1-8C9A-4A96-9160-C9EED3D67494Q33928743-0FDF9534-50A5-40F5-916B-3F435245BB70Q34302049-B7F3EACA-4267-4B34-BC47-EDB440650106Q34634185-F3E637DE-B049-4608-A3E2-FFAA13006A98Q34654334-88B65D94-FF4B-4E96-A7A5-6B1B52E9B824Q34975366-CF69153F-F712-4C24-9FB1-A3707994A4A2Q35111716-53CA0F2A-EC70-4B0D-89B3-0EE0827E51B9Q35589206-35DFA1CA-F939-4AC6-B2F6-03C8300306CCQ35609631-5DB628EB-270C-4AC4-B236-64EDE7728F13Q36063891-3F6BB49C-9DB7-4821-BADA-EBFB1D91546DQ36676458-5B836531-F2B7-455A-A925-79D253B95DD5Q36741850-1244F868-DAF6-4038-8219-FA8E4425E51AQ36776463-F42076A3-D79A-4F12-88E6-9577B448E448Q36783709-15EFED1E-C445-4559-BFCC-D45350656061Q36846338-0B5EE61E-7207-40A8-A756-2F64905F7C08Q36860357-B9C1435D-1CB3-43CA-889D-2C5E853EBA28Q36888845-5A4A9949-3D4B-4437-BFB3-30F4F813B3C2Q36894127-58B3D454-983B-4C59-A57A-1E69F80FAE93Q36899514-ADF2C020-F9D4-421C-A790-4CF8FC6F3764Q36900109-EDF36213-F645-48BE-B0E0-15BC1F059EB7Q36902393-F896DB19-5AF0-45C5-B489-C22A8D832A51Q36914545-68C66D66-92CF-469D-8AC4-90D28278DDECQ36924977-16D9C64C-ADF0-44B2-B91C-ABDE51C51D53Q36951425-D512FD2C-35A6-46AA-8647-ABE10B140884Q36963802-C220E1FB-C7A3-4895-99CC-F28B03CC79C0Q37187716-DC3B434A-DF23-4C5F-826D-FBDB86CC2FAEQ37409990-96126CE8-A344-4012-98FB-C784B63C31BAQ37412857-4E82B220-F543-4270-8D81-3A13EB3356EEQ37420705-C58267DE-762C-4A7C-8032-8FBF2C5DF9D3Q37551357-C3F01BD8-811C-4F76-A83C-B313C104DE4AQ37559044-F13A0D3F-FC52-4B9B-BDAA-44CAA4CBC42AQ37680879-96346ABC-FBF5-47F8-A3C8-D6DC3118F170Q37849259-20728FD2-49F7-4E02-9CE5-B46E160C92AFQ38142258-7DB61F08-6D4F-4B5D-87E1-39ECAB95858AQ39059515-F68F4741-9042-4D75-BFBD-6928CCEF86EA
P2860
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Activation of the c-abl oncoge ...... lar in vitro kinase properties
@en
type
label
Activation of the c-abl oncoge ...... lar in vitro kinase properties
@en
prefLabel
Activation of the c-abl oncoge ...... lar in vitro kinase properties
@en
P2093
P2860
P356
P1476
Activation of the c-abl oncoge ...... lar in vitro kinase properties
@en
P2093
P2860
P304
P356
10.1128/MCB.5.1.204
P407
P577
1985-01-01T00:00:00Z